BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
February 20 2020 - 7:00AM
Business Wire
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or
the “Company”), a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders, today announced
that Roberto Bellini, President and Chief Executive Officer of
BELLUS Health, will participate in two upcoming healthcare investor
conferences.
Conference Presentation Details:
Event: SVB Leerink 9th Annual Global Healthcare
Conference
Date/Time: Thursday, February 27, 2020 at 10:00 a.m.
EST
Location: New York, NY
Event: Cowen and Company's 40th Annual Health Care
Conference
Date/Time: Tuesday, March 3, 2020 at 8:00 a.m. EST
Location: Boston, MA
Live webcasts from the Leerink fireside chat and the Cowen
conference presentation may be accessed on the Events and
Presentations page under the Investors & News section of BELLUS
Health's website at www.bellushealth.com. Following the events,
archived webcasts and presentations will be available on the
Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders. The Company's
product candidate, BLU-5937, is being developed for the treatment
of chronic cough and chronic pruritus.
Chronic cough, the lead indication for BLU-5937, is a cough
lasting more than eight weeks and is associated with significant
adverse physical, social and psychosocial effects on health and
quality of life. It is estimated that approximately 26 million
adults in the United States suffer from chronic cough with more
than 2.6 million having refractory chronic cough lasting for more
than a year. There is no specific therapy approved for refractory
chronic cough and treatment options are limited.
Chronic pruritus, commonly known as chronic itch, is an
irritating sensation that leads to scratching, and persists for
longer than six weeks, which can be debilitating and has a
significant impact on quality-of-life. It is a hallmark of many
conditions, including atopic dermatitis (“AD”). It is estimated
that chronic pruritus associated with AD affects more than 16.9
million adults in the United States.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200220005180/en/
Investors: BELLUS Health François
Desjardins Vice-President, Finance 450-680-4525
fdesjardins@bellushealth.com
Solebury Trout Chad Rubin 646-378-2947 crubin@troutgroup.com
Media: Solebury Trout Joshua R.
Mansbach 646-378-2964 jmansbach@troutgroup.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Aug 2024 to Sep 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Sep 2023 to Sep 2024